Ameriprise
EWTX icon

Ameriprise’s Edgewise Therapeutics EWTX Stock Holding History

Ameriprise’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200,661
Closed -$6.32M – 4146
2026
Q1 		$6.32M Sell
200,661
-1,636
-0.8% -$47.2K ﹤0.01% 2280
2025
Q4 		$5.02M Buy
+202,297
New +$4.06M ﹤0.01% 2431
2025
Q2 		– Sell
-13,167
Closed -$290K – 4012
2025
Q1 		$290K Sell
13,167
-9,417
-42% -$247K ﹤0.01% 3688
2024
Q4 		$603K Buy
+22,584
New +$719K ﹤0.01% 3452

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise's EWTX Position: Q2 2026 in Review

Ameriprise sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 200,661 shares — an estimated $6.32M sold.

Ameriprise first reported a position in EWTX in Q4 2024 and held it in 4 quarters. The position peaked at $6.32M in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Ameriprise reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ameriprise sold 200,661 Edgewise Therapeutics shares in Q2 2026, an estimated $6.32M.
  • Ameriprise first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 4 quarters.
  • Ameriprise's Edgewise Therapeutics position peaked at $6.32M in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.